Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the Gingiva
- Conditions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Innoventus Project AB
- Target Recruit Count
- 10
- Registration Number
- NCT00689143
- Locations
- 🇸🇪
Dept of Oral & Maxillofacial Surgery, Uppsala, Sweden
Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00673179
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 41
- Registration Number
- NCT00669318
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00669734
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
- Conditions
- Adult Acute Myeloblastic Leukemia With Maturation (M2)Untreated Adult Acute Myeloid LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Erythroleukemia (M6a)de Novo Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00462605
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Vaccine Therapy in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019097
- Locations
- 🇺🇸
Arkansas Cancer Research Center, Little Rock, Arkansas, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Medicine Branch, Bethesda, Maryland, United States
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
- Conditions
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019890
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00381004
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
- Conditions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Favrille
- Target Recruit Count
- 480
- Registration Number
- NCT00324831
- Locations
- 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Veeda Oncology
- Target Recruit Count
- 35
- Registration Number
- NCT00313482
- Locations
- 🇺🇸
Veeda Oncology, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.